Clinical trials
Pulmonary Embolism trials in Russia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 4 |
| 2009 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 3 |
| 2017 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 19 |
| Recruiting | 6 |
| Unknown status | 3 |
| Not yet recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pirogov Russian National Research Medical University | 5 |
| Bristol-Myers Squibb | 4 |
| Bayer | 3 |
| Daiichi Sankyo | 3 |
| Meshalkin Research Institute of Pathology of Circulation | 2 |
| Supergene, LLC | 2 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1 |
| Eurasian Association of Therapists | 1 |
| Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 1 |
| GlaxoSmithKline | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pulmonary Embolism | 30 |
| Venous Thrombosis | 20 |
| Venous Thromboembolism | 13 |
| Thrombosis | 6 |
| COVID-19 | 3 |
| Thromboembolism | 3 |
| Arrhythmias, Cardiac | 2 |
| Atrial Fibrillation | 2 |
| Cardiovascular Diseases | 2 |
| Embolism and Thrombosis | 2 |
Trials
Showing 26 to 30 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.